Lloyd and his wife are grateful for the Oncotype DX Genomic Prostate Score.
When Lloyd, a financial executive, was diagnosed with early-stage prostate cancer in his mid-fifties, he was inclined to do whatever was recommended to treat his cancer. After further research, however, he learned that most early-stage disease is not aggressive and may not need immediate treatment.
“Like many men, my first reaction to my diagnosis was fear. I was ready for radiation or surgical treatment, but the likely side effects of treatment – sexual and urinary dysfunction – led my wife, Joan, and me to seek more information.”
“Genomic testing determined that my early-stage cancer was not aggressive, meaning that I could choose active surveillance instead of invasive treatment.”
Lloyd began his search for more information about his treatment options. He asked for a second opinion, and the urologist he spoke with mentioned that the Oncotype DX Genomic Prostate Score (GPS) test could help him better understand the biological behavior of his cancer. When Lloyd received a low Oncotype DX GPS result, he knew he would not need immediate aggressive treatment. “Genomic testing determined that my early-stage cancer was not aggressive, meaning that I could choose active surveillance instead of invasive treatment,” said Lloyd. His active surveillance treatment plan consisted of regular check-ups and testing to monitor and ensure his cancer was not progressing
A few years later, as part of Lloyd’s regular testing schedule, his PSA and a biopsy indicated that he needed surgery. “I am still very happy I chose my treatment path as I did, and I was able to delay surgery for almost 6 years. I put my trust in the Oncotype test and the science behind it, and it gave me and my doctors a clearer understanding of what the cancer was doing.”
Back to Featured Stories